DUBLIN--(BUSINESS WIRE)--Sep 14, 2018--The "Bronchitis - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Bronchitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Bronchitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 3, 4 and 1 respectively.

Bronchitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Companies Featured

Advanced Inhalation Therapies (AIT) Ltd. AstraZeneca PLC Daewon Pharm Co. Ltd. DBV Technologies SA F. Hoffmann-La Roche Ltd. Han Wha Pharma Co. Ltd. Icure Pharmaceutical Inc. Kyorin Pharmaceutical Co Ltd. Merck & Co. Inc. Onspira Therapeutics Inc. Orbis Biosciences Inc. Therabron Therapeutics Inc.

Key Topics Covered

1. Introduction

2. Report Coverage

3. Bronchitis - Overview

4. Bronchitis - Therapeutics Development

5. Bronchitis - Therapeutics Assessment

6. Bronchitis - Companies Involved in Therapeutics Development

7. Bronchitis - Drug Profiles

8. Bronchitis - Dormant Projects

9. Bronchitis - Discontinued Products

10. Bronchitis - Product Development Milestones

Featured News & Press Releases (2017-2018)

AIT Therapeutics Receives Patent Allowance for Delivery of Inhaled Nitric Oxide at Concentrations of at Least 160ppm for Treatment of Bronchiolitis in Infants AIT Therapeutics Announces Publication of Its Phase 2 Trial in Bronchiolitis Patients in the Pediatric Pulmonology Journal AIT Therapeutics to Hold Clinical Update Meeting Therabron Therapeutics Receives Orphan Drug Designation in the European Union for CG367, Indicated for the Treatment of Bronchiolitis Obliterans Syndrome

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/sgp4bh/bronchitis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180914005393/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs,Bronchitis Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/14/2018 11:44 AM/DISC: 09/14/2018 11:44 AM